Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:970897rdf:typepubmed:Citationlld:pubmed
pubmed-article:970897lifeskim:mentionsumls-concept:C0032961lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0033371lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0392533lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0205329lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0441469lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:970897lifeskim:mentionsumls-concept:C0701351lld:lifeskim
pubmed-article:970897pubmed:issue4lld:pubmed
pubmed-article:970897pubmed:dateCreated1976-11-21lld:pubmed
pubmed-article:970897pubmed:abstractTextA 24 year old woman who had epilepsy since the age of 7 years and who was still using antiepileptics, developed an excessive mamary growth (gigantomastia) during pregnancy. Treatment with CB 154 (Sandoz), 2 Br-alpha-ergocryptin in a dose of 2.5 mg three times a day from the 27th week of pregnancy, resulted in prompt improvement with a corresponding decrease in the plasma prolactin, return of the breast temperature to normal, and disappearance of the EEG-abnormalities. After parturition and subsequent mammoplasty the woman soon became pregant again. During this pregnancy, which terminated in the birth of a normal child, treatment with CB 154 was started early and continued throughout pregnancy with success and without side effects.lld:pubmed
pubmed-article:970897pubmed:languageenglld:pubmed
pubmed-article:970897pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:citationSubsetIMlld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:970897pubmed:statusMEDLINElld:pubmed
pubmed-article:970897pubmed:issn0355-9521lld:pubmed
pubmed-article:970897pubmed:authorpubmed-author:KullanderSSlld:pubmed
pubmed-article:970897pubmed:issnTypePrintlld:pubmed
pubmed-article:970897pubmed:volume65lld:pubmed
pubmed-article:970897pubmed:ownerNLMlld:pubmed
pubmed-article:970897pubmed:authorsCompleteYlld:pubmed
pubmed-article:970897pubmed:pagination227-33lld:pubmed
pubmed-article:970897pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-H...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-P...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-P...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-B...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-P...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-F...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-A...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-P...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-M...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-D...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-E...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-E...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-C...lld:pubmed
pubmed-article:970897pubmed:meshHeadingpubmed-meshheading:970897-B...lld:pubmed
pubmed-article:970897pubmed:year1976lld:pubmed
pubmed-article:970897pubmed:articleTitleEffect of 2 br-alpha-ergocryptin (CB 154) on serum prolactin and the clinical picture in a case of progressive gigantomastia in pregnancy.lld:pubmed
pubmed-article:970897pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:970897pubmed:publicationTypeCase Reportslld:pubmed